Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

nts, short-term investments and net working capital of $5,635,365, $6,825,190 and $9,088,712, respectively. The Company currently believes that it has adequate financial resources to continue into the fourth quarter of fiscal 2008 based on planned research and development expenditures and operating costs.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to Follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

INTERIM BALANCE SHEETS

(Unaudited)

-------------------------------------------------------------------------

May 31, November 30,

2008 2007

$ $

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents 8,543,124 5,635,365

Short-term investments - 6,825,190

Receivables 185,672 230,126

Refundable tax credits 600,000 400,000

Prepaid expenses
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Pharmaco-Kinesis Corporation (PKC) announced today that ... Shutters on the Beach in Santa Monica, ... the Company,s innovative Metronomic Biofeedback Pump (MBP), a fully ... over time to a target site of the human ... system in real-time.  ...
(Date:5/26/2015)... -- Mr. Kevin Xu , President of MEBO International, ... and President Bill Clinton for their sympathy ... Rongxiang Xu , Kevin,s father. As ... time, Dr. Xu,s commitment to the advancement of science and ... not be forgotten. As a renowned life scientist, Dr. Xu ...
(Date:5/26/2015)... TORONTO , May 26, 2015 /PRNewswire/ - Fluorinov ... appointment of Luke M. Beshar to its ... adding financial and pharmaceutical industry expertise as Fluorinov accelerates ... of the Fluorinov team, it is a pleasure to ... had a significant impact on the strategy, financial strength ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... officially joining the Alliance for Regenerative Medicine (ARM). ... fostering research, development, investment, and commercialization of transformational ... PRC Clinical, the California-based CRO focused in ... in stem cell and regenerative research working with ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3
... The National Eye ... grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment ... ... (NEI), a division of the National Institutes of Health (NIH), awarded a $2.18 million grant ...
... ... a world-leading provider of advanced flow measurement, control, and level solutions, ... Product Manager effective November 30, 2009. He will lead Brooks Instrument’s ... the world. He is joining Brooks Instrument from Lafarge Corp, a ...
... , SAN DIEGO, Dec. 10 ... announces the release of SampleWare 3.1 software system for laboratory ... now includes an audit trail functionality that tracks user and ... stored sample. , The addition of the audit trail ...
Cached Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Biomatrica Launches SampleWare 3.1 2Biomatrica Launches SampleWare 3.1 3
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... and flu expert is calling for mandatory vaccination of ... protecting patients and hospital staff from widespread outbreaks of ... researchers show that voluntary vaccination programs don't do the ... from influenza, many of them elderly or ill, with ...
... this week in Nature shows for the first time ... cells that regulate daily activity of Drosophila melanogaster (fruit ... and evening activity and are maintained in synch even ... periods of time. , This daily resetting signal ...
... a whiff of food that has made them sick in ... ?and to prevent them from eating that food again. It's ... biology that it occurs in a broad range of species. ... smells associated with foods that have made them ill. ...
Cached Biology News:Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3A resetting signal keeps circadian rhythm on track in Drosophila fruit flies 2Worms know bad food when they smell it 2Worms know bad food when they smell it 3Worms know bad food when they smell it 4
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... flasks have triple baffles located at the ... maximal oxygen transfer to culture medium. These ... wide range of optional caps are available ... caps for ease of sorting and identification ...
...
... These 2800mL wide mouth PYREX Fernbach-style culture ... center of the flask bottom to achieve ... triple baffled flasks have a Delong-style 38mm ... steel closures. For plastic closures see Nos. ...
Biology Products: